Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
02 September 2020 | Story Lacea Loader | Photo Charl Devenish
Deputy Minister visit
From the left are: Deputy Minister of Higher Education, Science and Technology, Buti Manamela; Prof Prakash Naidoo, Vice-Rector: Operations at the UFS; and Dr Ramneek Ahluwalia, Chief Executive Officer of Higher Health.
“The work that the University of the Free State (UFS) is doing to ensure that students get the necessary support is quite impressive. The university is saving the academic year to save lives.” These were the words of the Deputy Minister of Higher Education, Science and Technology, Buti Manamela, during a visit to the university’s Bloemfontein Campus on 31 August 2020.

The visit was part of the Deputy Minister’s visit to higher education institutions in Bloemfontein to assess the academic state of readiness and to monitor the safety protocols for the phased re-opening of campuses during Level 2 of the national lockdown.

The delegation, which also consisted of representatives from Higher Health led by the Chief Executive Officer Dr Ramneek Ahluwalia, attended a briefing session in the Council Chambers before visiting various venues on campus. In his opening and welcoming remarks, Prof Prakash Naidoo, Vice-Rector: Operations, said that the safety, health, and well-being of staff and students remain the university’s priority. “Extensive planning has gone into making sure that the university complies with the national COVID-19 protocols and regulations and that our campuses are safe and ready for the return of students. Sufficient hygiene measures are in place, as well as adaptions to ensure physical distancing. The wearing of masks, physical distancing, and hand sanitising remain compulsory on all the campuses,” said Prof Naidoo.

“A Special Executive Group (SEG) was already established by the Rector and Vice-Chancellor, Prof Francis Petersen, at the beginning of March 2020. The SEG meets weekly to discuss and decide on the university’s response to COVID-19 as this pandemic develops over time. Consisting of eight task teams, the SEG is the decision-making entity that responds rapidly and in a coordinated manner to combat the threats to business continuity. One of the task teams is specifically looking at the wellness of our students and staff to make sure that this important aspect is taken care of,” said Prof Naidoo.

During a presentation of the university’s Multimodal Teaching and Learning Plan for the completion of the 2020 academic year, Prof Francois Strydom, Senior Director: Centre for Teaching and Learning, said that the university has an evidence-based approach towards remote multimodal teaching, learning, and assessment. “For instance, our vulnerable students were identified early in the lockdown, and 16 strategies were put in place to ensure that no student is left behind. 99,95% of our students were active on Blackboard. We are developing plans for the 0,05% of students who were not able to participate in learning, so that they can continue their learning journey with the UFS,” said Prof Strydom.

In his closing remarks, Deputy Minister Manamela commended the university management on the initiatives to save the academic year. He also indicated his appreciation for the informative session and encouraged the university to keep on motivating students and staff to be attentive to their behaviour and to remain careful about their health and well-being.

The programme was concluded with a visit to a number of venues on campus, including the examination venues, the Health and Wellness Clinic, the Pathogen Research Laboratory of the Division of Virology and a student housing unit.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept